Time: 18 November, 14:30-15:30 CET
Manica Balasegaram, Executive Director, Global Antibiotic Research and Development Partnership
Dr Amal Saif Al Al-Maani, Director of Central Department of Infection Prevention & Control, Ministry of Health, Oman
Ingrid Stenstadvold Ross, Secretary General, Norwegian Cancer Society
Daniel Berman, Lead, Longitude Prize
Sujith J. Chandy, Head of ReAct Asia Pacific
The emergence of antibiotic resistant bacteria poses a significant and growing threat to cancer treatment outcomes. People with cancer are more susceptible to infections due to the lowering of immune defences, while surgery and treatments like bone marrow transplants, radiotherapy and chemotherapy put the immune system under immense pressure. As many as 1 in 5 cancer patients undergoing treatment are hospitalized due to infection and antibiotics are the main line of defense.
Antibiotics are a key and indispensable part of cancer treatment that we have taken for granted, and we owe it to our patients to ensure we continue to have treatments for infections at our disposal in order to save lives from cancer. To mark World Antimicrobial Awareness Week, join this panel of experts to explore what role the infectious diseases and cancer care communities can play in effort to develop new antibiotics and fight drug resistance.